Bristol Myers Squibb gets EC nod for expanded use of Breyanzi
https://seekingalpha.com/news/4420725-bristol-myers-squibb-gets-ec-nod-for-expanded-use-of-breyanzi?source=feed_sector_healthcare
Mar 14, 2025 -
0
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
https://www.zacks.com/stock/news/2327848/regeneron-s-bispecific-antibody-obtains-ec-nod-for-lymphoma?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2327848
Aug 27, 2024 - REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
0
Ecopetrol S.A. (EC) Q2 2024 Earnings Call Transcript
https://seekingalpha.com/article/4715380-ecopetrol-s-ec-q2-2024-earnings-call-transcript?source=feed_sector_transcripts
Aug 17, 2024 - Ecopetrol S.A. (NYSE:NYSE:EC) Q2 2024 Earnings Conference Call August 14, 2024 10:00 AM ETCompany ParticipantsRicardo Roa - Chief Executive OfficerRafael...
0
Pfizer hemophilia B gene therapy Durveqtix wins EC authorization
https://seekingalpha.com/news/4128465-pfizer-hemophilia-b-gene-therapy-durveqtix-wins-ec-authorization?source=feed_sector_healthcare
Jul 25, 2024 - Pfizer's gene therapy Durveqtix receives conditional marketing authorization from the European Commission for hemophilia B. Read more here.
0
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
https://www.zacks.com/stock/news/2298565/mirum-mirm-gets-ec-approval-for-livmarli-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2298565
Jul 09, 2024 - The European Commission approves Mirum's (MIRM) Livmarli for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.
0
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
https://www.zacks.com/stock/news/2296528/regeneron-regn-sny-win-ec-approval-for-dupixent-for-copd?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2296528
Jul 03, 2024 - Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
0
How to Find Strong Oils and Energy Stocks Slated for Positive Earnings Surprises
https://www.zacks.com/stock/news/2292711/how-to-find-strong-oils-and-energy-stocks-slated-for-positive-earnings-surprises?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2292711
Jun 25, 2024 - The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
0
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
https://www.zacks.com/stock/news/2286218/roche-rhhby-nsclc-drug-alecensa-gets-ec-nod-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2286218
Jun 10, 2024 - Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.
0
Equinor (EQNR) Teams Up With Seeq for Digital Transformation
https://www.zacks.com/stock/news/2282767/equinor-eqnr-teams-up-with-seeq-for-digital-transformation?cid=CS-ZC-FT-analyst_blog|company_news_energy_sector-2282767
Jun 03, 2024 - Per the agreement, Equinor (EQNR) will integrate Seeq's Industrial Analytics and AI platform to optimize its engineering processes and maximize production.
0
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
https://www.zacks.com/stock/news/2281590/bristol-myers-bmy-gets-ec-nod-for-opdivo-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2281590
May 30, 2024 - Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
0
Page 1>